Radiofrequency Ablation for Carcinoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Carcinoma+10 More
Radiofrequency Ablation - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial studies radiofrequency ablation to treat patients with benign or low-risk thyroid nodules. The goal is to learn if it is as effective as surgery and if it has a better recovery response.

Eligible Conditions
  • Carcinoma
  • Thyroid Gland
  • Thyroid Gland Nodule
  • Carcinoma, Papillary
  • Thyroid Gland Follicular Tumor of Uncertain Malignant Potential

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Baseline up to 12 months

Month 12
Changes in thyroid nodule size
Month 12
Cost of ultrasound-guided radiofrequency ablation (RFA)
Sonographic features of nodules
Treatment response that affect quality of life

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Treatment (RFA)
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Radiofrequency Ablation · No Placebo Group · Phase < 1

Treatment (RFA)Experimental Group · 2 Interventions: Radiofrequency Ablation, Quality-of-Life Assessment · Intervention Types: Procedure, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiofrequency Ablation
2013
Completed Phase 4
~1040

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline up to 12 months

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,671 Total Patients Enrolled
258 Trials studying Carcinoma
36,181 Patients Enrolled for Carcinoma
Kim O LearnedPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patient is medically fit to undergo local anesthesia with or without conscious sedation.
The thyroid nodule is indeterminate cytology, follicular neoplasm, PTC without metastasis or locally recurrent thyroid cancer < 2 cm in the largest dimension.
Patient requests treatment of benign thyroid nodule.
Patient is able to understand and give consent to participation in the study.
You have a solitary thyroid nodule or dominant nodule that is well-defined in multinodular goiter.
You have a single lesion that is amenable to trans-isthmus approach.
The entire nodule is visible on ultrasound without significant extension posterior to trachea or mediastinal component.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Alaska50.0%
South Dakota50.0%
How old are they?
65+50.0%
18 - 6550.0%
What site did they apply to?
M D Anderson Cancer Center100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%